Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
NCT07036172 on ClinicalTrials.gov · last registry update 2025-06-25
Recruiting now, toward 460 participants. Its estimated completion date, April 2026, has passed with no update to the record. Primary outcome, as filed: The percentage change in body weight from baseline to week 44. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 460
- Started
- 2025-01-03
- Primary completion
- 2026-04 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The percentage change in body weight from baseline to week 44
Conditions studied
Obesity Control
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.